Online citations, reference lists, and bibliographies.

Rosuvastatin For Lowering Lipids

S. Adams, S. Sekhon, J. M. Wright
Published 2014 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Background Rosuvastatin is one of the most potent statins and is currently widely prescribed. It is therefore important to know the dose-related magnitude of effect of rosuvastatin on blood lipids. Objectives Primary objective To quantify the effects of various doses of rosuvastatin on serum total cholesterol, low-density lipoprotein (LDL)-cholesterol, high-density lipoprotein (HDL)-cholesterol, non-HDL-cholesterol and triglycerides in participants with and without evidence of cardiovascular disease. Secondary objectives To quantify the variability of the effect of various doses of rosuvastatin. To quantify withdrawals due to adverse effects (WDAEs) in the randomized placebo-controlled trials. Search methods We searched the Cochrane Central Register of Controlled Trials (CENTRAL) Issue 10 of 12, 2014 in The Cochrane Library, MEDLINE (1946 to October week 5 2014), EMBASE (1980 to 2014 week 44), Web of Science Core Collection (1970 to 5 November 2014) and BIOSIS Citation Index (1969 to 31 October 2014). No language restrictions were applied. Selection criteria Randomized controlled and uncontrolled before-and-after trials evaluating the dose response of different fixed doses of rosuvastatin on blood lipids over a duration of three to 12 weeks. Data collection and analysis Two review authors independently assessed eligibility criteria for studies to be included and extracted data. WDAEs information was collected from the placebo-controlled trials. Main results One-hundred and eight trials (18 placebo-controlled and 90 before-and-after) evaluated the dose-related efficacy of rosuvastatin in 19,596 participants. Rosuvastatin 10 to 40 mg/day caused LDL-cholesterol decreases of 46% to 55%, when all the trials were combined using the generic inverse variance method. The quality of evidence for these effects is high. Log dose-response data over doses of 1 to 80 mg, revealed strong linear dose-related effects on blood total cholesterol, LDL-cholesterol and non-HDL-cholesterol. When compared to atorvastatin, rosuvastatin was about three-fold more potent at reducing LDL-cholesterol. There was no dose-related effect of rosuvastatin on blood HDL-cholesterol, but overall, rosuvastatin increased HDL by 7%. There is a high risk of bias for the trials in this review, which would affect WDAEs, but unlikely to affect the lipid measurements. WDAEs were not statistically different between rosuvastatin and placebo in 10 of 18 of these short-term trials (risk ratio 0.84; 95% confidence interval 0.48 to 1.47). Authors' conclusions The total blood total cholesterol, LDL-cholesterol and non-HDL-cholesterol-lowering effect of rosuvastatin was linearly dependent on dose. Rosuvastatin log dose-response data were linear over the commonly prescribed dose range. Based on an informal comparison with atorvastatin, this represents a three-fold greater potency. This review did not provide a good estimate of the incidence of harms associated with rosuvastatin because of the short duration of the trials and the lack of reporting of adverse effects in 44% of the placebo-controlled trials.
This paper references
10.1177/1074248412439470
Effect of Rosuvastatin Monotherapy and in Combination With Fenofibrate or Omega-3 Fatty Acids on Serum Vitamin D Levels
Stefania E. Makariou (2012)
10.1016/S0002-9149(02)02994-6
Comparative effects of rosuvastatin and atorvastatin across their dose ranges in patients with hypercholesterolemia and without active arterial disease.
D. Schneck (2003)
10.2217/pgs.13.115
Effects of polymorphisms in ABCG2, SLCO1B1, SLC10A1 and CYP2C9/19 on plasma concentrations of rosuvastatin and lipid response in Chinese patients.
H. Lee (2013)
10.1016/S0002-9343(98)00187-9
The lipoprotein and coronary atherosclerosis study (LCAS): lipid and metabolic factors related to atheroma and clinical events.
J. Herd (1998)
10.2165/00044011-199510030-00001
Double-Blind Comparison of the Efficacy and Tolerability of Simvastatin and Fluvastatin in Patients with Primary Hypercholesterolaemia
L. Ose (1995)
10.1097/MCA.0b013e32830d27d2
Short-term effects of fluvastatin therapy on plasma interleukin-10 levels in patients with chronic heart failure
A. Tekin (2008)
10.1016/J.VPH.2003.09.002
Time-dependent lipid response on fluvastatin therapy of patients with hypercholesterolemia sensitive to apoE phenotype.
A. Dergunov (2003)
10.1016/J.IJCARD.2003.04.009
Efficacy and safety of fluvastatin therapy for hypercholesterolemia after heart transplantation: results of a randomised double blind placebo controlled study.
B. O'Rourke (2004)
10.1016/j.atherosclerosis.2013.10.007
Intensive lipid lowering therapy with titrated rosuvastatin yields greater atherosclerotic aortic plaque regression: Serial magnetic resonance imaging observations from RAPID study.
M. Yogo (2014)
10.3111/13696998.2012.726674
Cost-effectiveness analysis of rosuvastatin vs generic atorvastatin in Spain
V. Barrios (2012)
10.1345/aph.1E367
Cost-Effectiveness of Fluvastatin following Successful First Percutaneous Coronary Intervention
T. Delea (2005)
10.1016/S0002-9149(03)00003-1
Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in special population groups.
J. Blasetto (2003)
10.1097/00005344-200003000-00005
Effects of fluvastatin treatment on red blood cell Na+ transport systems in hypercholesterolemic subjects.
A. Saitta (2000)
10.1016/S0002-9149(05)80033-5
Improvement of myocardial perfusion by short-term fluvastatin therapy in coronary artery disease.
H. Eichstaedt (1995)
10.1016/0002-9343(94)90233-X
Treatment of primary hypercholesterolemia: fluvastatin versus bezafibrate.
H. Greten (1994)
10.1007/s001980170106
The Effect of Fluvastatin on Parameters of Bone Remodeling
N. Bjarnason (2001)
10.1016/j.amjcard.2007.08.035
Effects of maximal doses of atorvastatin versus rosuvastatin on small dense low-density lipoprotein cholesterol levels.
M. Ai (2008)
10.7326/0003-4819-125-12-199612150-00011
Dose-Response Characteristics of Cholesterol-Lowering Drug Therapies: Implications for Treatment
G. Schectman (1996)
10.1185/030079906X112462
Treating to target patients with primary hyperlipidaemia:comparison of the effects of ATOrvastatin and ROSuvastatin (the ATOROS study)
H. Milionis (2006)
10.1016/J.EHJSUP.2004.01.010
Non-high-density lipoprotein cholesterol as a risk factor: addressing risk associated with apolipoprotein B-containing lipoproteins
M. Chapman (2004)
10.2165/00003495-199400472-00011
Efficacy and Safety of Fluvastatin, a New HMG CoA Reductase Inhibitor, in Elderly Hypercholesterolaemic Women
G. Baggio (2012)
Chapter 12: Interpreting results and drawing conclusions
H. Schünemann (2011)
10.1097/00001721-199904000-00004
Increasing plasma fibrinogen, but unchanged levels of intraplatelet cyclic nucleotides, plasma endothelin-1, factor VII, and neopterin during cholesterol lowering with fluvastatin.
A. Gottsäter (1999)
10.1111/J.1524-4733.2005.00055.X
Cost-effectiveness of rosuvastatin compared with other statins from a managed care perspective.
J. Benner (2005)
10.1016/S0021-9150(00)00495-0
A prospective study of paraoxonase gene Q/R192 polymorphism and severity, progression and regression of coronary atherosclerosis, plasma lipid levels, clinical events and response to fluvastatin.
S. Turban (2001)
10.1177/107424849600100203
A Comparison of the Tolerability and Efficacy of Lovastatin 20 mg and Fluvastatin 20 mg in the Treatment of Primary Hypercholesterolemia
M. Berger (1996)
10.1177/000331979804901006
Vasodilatory Capacity of Forearm Resistance Vessels Is Augmented in Hypercholesterolemic Patients After Treatment with Fluvastatin
H. Schobel (1998)
10.1016/S0021-9150(99)00062-3
The effect of fluvastatin on cardiac events in patients with symptomatic coronary artery disease during one year of treatment.
G. Riegger (1999)
10.1016/J.ATHEROSCLEROSIS.2007.06.028
A dose-titration and comparative study of rosuvastatin and atorvastatin in patients with homozygous familial hypercholesterolaemia.
A. D. Marais (2008)
10.1157/13123836
Rosuvastatina para tratamiento de la dislipidemia en pacientes infectados con VIH en tratamiento antirretroviral de gran actividad. Experiencia preliminar
E. Bottaro (2008)
10.1016/J.EJPHAR.2007.09.019
Effect of rosuvastatin treatment on plasma visfatin levels in patients with primary hyperlipidemia.
M. Kostapanos (2008)
10.1177/1074248412463611
Effects of Manidipine Plus Rosuvastatin Versus Olmesartan Plus Rosuvastatin on Markers of Insulin Resistance in Patients With Impaired Fasting Glucose, Hypertension, and Mixed Dyslipidemia
E. Liberopoulos (2013)
10.1097/01.HJR.0000159276.96437.1C
Rosuvastatin is cost-effective in treating patients to low-density lipoprotein-cholesterol goals compared with atorvastatin, pravastatin and simvastatin: analysis of the STELLAR trial.
M. Hirsch (2005)
10.1253/CIRCJ.72.722
Fluvastatin improves arterial stiffness in patients with coronary artery disease and hyperlipidemia: a 5-year follow-up study.
M. Hongo (2008)
10.1157/13113929
Rosuvastatina y metformina reducen la inflamación y el estrés oxidativo en pacientes con hipertensión y dislipemia
A. Gómez-García (2007)
10.1093/NDT/17.8.1513
Fluvastatin prevents development of arterial stiffness in haemodialysis patients with type 2 diabetes mellitus.
A. Ichihara (2002)
Statin treatment and exercise: Is there an additive anti -inflammatory effect?
P. Coen (2008)
10.1007/BF02849954
Effects of fluvastatin treatment on lipid profile, C-reactive protein trend, and renal function in dyslipidemic patients with chronic renal failure
L. Lullo (2005)
10.1185/030079907X187847
Efficacy and safety of extended-release fluvastatin in Turkish patients with hypercholesterolaemia: TULiPS (Turkish Lipid Study)
B. Ilerigelen (2007)
[Efficacy and safety of combined statin-fenofibrates therapy compared with monotherapy in patients with mixed hyperlipidemia and high risk of coronary heart disease].
L. Kłosiewicz-latoszek (2003)
10.1177/1074248407306676
Dose-Dependent Effect of Rosuvastatin Treatment on Urinary Protein Excretion
M. Kostapanos (2007)
10.1002/14651858.CD004816.pub5
Statins for the primary prevention of cardiovascular disease.
F. Taylor (2013)
Chapter 10: Addressing reporting biases
M. Egger (2011)
10.1007/978-94-011-5022-4_31
Lessons from Clinical Trials: LCAS and Other Studies
J. A. Herd (1998)
10.1016/J.CLINTHERA.2007.07.019
A 12-week, prospective, open-label analysis of the effect of rosuvastatin on triglyceride-rich lipoprotein metabolism in patients with primary dyslipidemia.
M. Kostapanos (2007)
10.1517/14656566.2011.591383
The effects of rosuvastatin alone or in combination with fenofibrate or omega 3 fatty acids on inflammation and oxidative stress in patients with mixed dyslipidemia
A. Agouridis (2011)
10.2165/10061630-000000000-00000
Efficacy and Safety of Fenofibric Acid Co-Administered with Low- or Moderate-Dose Statin in Patients with Mixed Dyslipidemia and Type 2 Diabetes Mellitus
P. Jones (2010)
10.5551/JAT.11.152
Clinical efficacy and safety of rosuvastatin in Japanese patients with heterozygous familial hypercholesterolemia.
H. Mabuchi (2004)
10.1007/s12265-014-9559-3
Baseline Very Low-Density Lipoprotein Cholesterol is Associated with the Magnitude of Triglyceride Lowering on Statins, Fenofibric Acid, or Their Combination in Patients with Mixed Dyslipidemia
A. Sharma (2014)
10.1016/S0011-393X(97)80068-9
Argentine multicenter evaluation of fluvastatin in the treatment of patients with hypercholesterolemia
Alfredo P Buzzi (1997)
10.1185/03007990802321709
Lipidomic approach to evaluate rosuvastatin and atorvastatin at various dosages: investigating differential effects among statins
S. Bergheanu (2008)
10.1161/01.CIR.99.4.475
Delayed response of myocardial flow reserve to lipid-lowering therapy with fluvastatin.
M. Güthlin (1999)
10.12659/MSM.883272
Lipid-lowering effect of fluvastatin in relation to cytochrome P450 2C9 variant alleles frequently distributed in the Czech population
H. Buzková (2012)
10.1016/j.ijcard.2009.05.051
Comparative effects of rosuvastatin and allopurinol on circulating levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with chronic heart failure.
D. Tousoulis (2010)
10.1016/j.atherosclerosis.2010.10.006
Effects of atorvastatin and rosuvastatin on thromboxane-dependent platelet activation and oxidative stress in hypercholesterolemia.
L. Puccetti (2011)
10.1002/14651858.CD008226.PUB3
Atorvastatin for lowering lipids
S. Adams (2015)
10.1016/j.ijcard.2010.02.019
High-dose rosuvastatin in chronic heart failure promotes vasculogenesis, corrects endothelial function, and improves cardiac remodeling--results from a randomized, double-blind, and placebo-controlled study.
S. Erbs (2011)
10.1016/S0002-9149(99)00471-3
Effects of fluvastatin on prothrombotic and fibrinolytic factors in type 2 diabetes mellitus.
K. Tan (1999)
10.1536/IHJ.54.33
Intensive lipid-lowering therapy for slowing progression as well as inducing regression of atherosclerosis in Japanese patients: subanalysis of the JART study.
T. Yamazaki (2013)
10.1097/00019501-200403000-00008
Rosuvastatin improves the atherogenic and atheroprotective lipid profiles in patients with hypertriglyceridemia
D. Hunninghake (2004)
10.1186/1475-2840-8-1
Omega 3 fatty acids induce a marked reduction of apolipoprotein B48 when added to fluvastatin in patients with type 2 diabetes and mixed hyperlipidemia: a preliminary report
P. Valdivielso (2009)
10.5551/JAT.11.56
Effects of fluvastatin in type 2 diabetic patients with hyperlipidemia: reduction in cholesterol oxidation products and VCAM-1.
Jing-Zhi Guan (2004)
10.1016/S0262-4079(06)61379-1
How green is your roof
Mike Garnham (2006)
10.1016/j.atherosclerosis.2009.10.046
Effects of rosuvastatin on myeloperoxidase levels in patients with chronic heart failure: a randomized placebo-controlled study.
I. Andreou (2010)
10.2165/00019053-200321001-00002
An Economic Analysis of the Atorvastatin Comparative Cholesterol Efficacy and Safety Study (ACCESS)
D. Smith (2012)
10.1177/000331970505600510
Starting with Rosuvastatin in Primary Hyperlipidemia—
H. Milionis (2005)
10.2165/00044011-199612030-00001
Efficacy and Tolerability of Fluvastatin and Simvastatin in Hypercholesterolaemic Patients
Karl-Ludwig Schulte (1996)
10.1093/EURHEARTJ/EHI482
A comparative study with rosuvastatin in subjects with metabolic syndrome: results of the COMETS study.
A. Stalenhoef (2005)
10.1016/j.jcmg.2012.11.004
Insulin resistance and LVH progression in patients with calcific aortic stenosis: a substudy of the ASTRONOMER trial.
R. Capoulade (2013)
10.1002/14651858.CD003824.pub2
Blood pressure-lowering efficacy of monotherapy with thiazide diuretics for primary hypertension.
Vijaya M Musini (2014)
10.1016/0002-9343(94)90165-1
Efficacy and safety of a combination fluvastatin-bezafibrate treatment for familial hypercholesterolemia: comparative analysis with a fluvastatin-cholestyramine combination.
E. Leitersdorf (1994)
10.1186/1476-7120-9-5
Evaluating the effectiveness of rosuvastatin in preventing the progression of diastolic dysfunction in aortic stenosis: A substudy of the aortic stenosis progression observation measuring effects of rosuvastatin (ASTRONOMER) study
D. Jassal (2011)
10.1016/S0002-9149(96)00684-4
Effect of fluvastatin on lipids and fibrinolysis in coronary artery disease.
M. Bevilacqua (1997)
10.1016/S0735-1097(98)00300-3
Treating patients with documented atherosclerosis to National Cholesterol Education Program-recommended low-density-lipoprotein cholesterol goals with atorvastatin, fluvastatin, lovastatin and simvastatin.
A. Brown (1998)
10.1016/0002-9149(94)90629-7
Combination therapy with fluvastatin and niacin in hypercholesterolemia: a preliminary report on safety.
T. Jacobson (1994)
10.2337/dc10-0357
The Effects of Fenofibric Acid Alone and With Statins on the Prevalence of Metabolic Syndrome and Its Diagnostic Components in Patients With Mixed Dyslipidemia
H. Bays (2010)
[The hypolipidemic effect of and tolerance for Lescol in treating hypercholesterolemia in hypertension patients (an analysis of the data from a multicenter study)].
D. Aronov (1995)
10.1007/s12325-010-0098-2
A crossover study of rosuvastatin and pitavastatin in patients with type 2 diabetes
Kazunori Yanagi (2011)
10.1016/j.jjcc.2012.07.008
Rosuvastatin-induced high-density lipoprotein changes in patients who underwent percutaneous coronary intervention for non-ST-segment elevation acute coronary syndrome.
K. H. Yun (2012)
10.1016/j.amjcard.2011.03.079
Safety and efficacy of ezetimibe added on to rosuvastatin 5 or 10 mg versus up-titration of rosuvastatin in patients with hypercholesterolemia (the ACTE Study).
H. Bays (2011)
10.1016/J.AHJ.2004.03.067
Fluvastatin reduces the impact of diabetes on long-term outcome after coronary intervention--a Lescol Intervention Prevention Study (LIPS) substudy.
C. Arampatzis (2005)
10.1016/S0828-282X(09)70480-5
Efficacy of alternate day versus daily dosing of rosuvastatin.
D. Dulay (2009)
10.2337/dc08-1681
Effects of Rosuvastatin and Atorvastatin on LDL and HDL Particle Concentrations in Patients With Metabolic Syndrome
R. Rosenson (2009)
10.1002/SIM.1186
Quantifying heterogeneity in a meta-analysis.
J. Higgins (2002)
10.1002/J.1875-9114.1998.TB03905.X
A comparison of fluvastatin 40 mg every other day versus 20 mg every day in patients with hypercholesterolemia.
J. Rindone (1998)
10.3275/8371
Effects of metformin plus rosuvastatin on hyperandrogenism in polycystic ovary syndrome patients with hyperlipidemia and impaired glucose tolerance
O. Celik (2012)
10.5551/JAT.9.48
Clinical effects of rosuvastatin, a new HMG-CoA reductase inhibitor, in Japanese patients with primary hypercholesterolemia: an early phase II study.
A. Yamamoto (2002)
10.2217/14622416.9.9.1217
Association between a frequent allele of the gene encoding OATP1B1 and enhanced LDL-lowering response to fluvastatin therapy.
P. Couvert (2008)
The effect of fluvastatin (Lescol) treatment on the clinical status and function of the liver in patients with ischemic heart disease
Kuril'skaia Te (1997)
スタチン新規処方の高コレステロール血症患者に対するストロングスタチン 3 剤の有効性の検討
順久 立石 (2011)
10.1159/000093200
Efficacy and Safety of Fluvastatin-Extended Release in Hypercholesterolemic Patients: Morning Administration Is Equivalent to Evening Administration
H. Scharnagl (2006)
10.1016/S0002-9343(01)00799-9
Achieving and maintaining National Cholesterol Education Program low-density lipoprotein cholesterol goals with five statins.
T. Andrews (2001)
10.1016/S0149-2918(03)80330-2
A multicenter, randomized, double-blind clinical trial comparing the low-density lipoprotein cholesterol-lowering ability of lovastatin 10, 20, and 40 mg/d with fluvastatin 20 and 40 mg/d.
M. Davidson (2003)
10.1016/j.ejim.2011.11.011
The effects of low-dose fluvastatin and valsartan combination on arterial function: a randomized clinical trial.
M. Lunder (2012)
10.1159/000013504
Efficiency of 1-Year Treatment with Fluvastatin in Hyperlipidemic Patients with Nephrotic Syndrome
F. Matzkies (1999)
10.1161/CIR.0b013e3182009701
Heart disease and stroke statistics--2011 update: a report from the American Heart Association.
V. Roger (2011)
10.1016/S0011-393X(03)00060-2
Effects of fluvastatin on plasma levels of low-density lipoprotein subfractions, oxidized low-density lipoprotein, and soluble adhesion molecules: a twenty-four-week, open-label, dose-increasing study.
Y. Homma (2003)
10.1136/bmj.326.7404.1423
Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis
M. Law (2003)
10.1007/s00109-002-0381-z
Effects of SREBF-1a and SCAP polymorphisms on plasma levels of lipids, severity, progression and regression of coronary atherosclerosis and response to therapy with fluvastatin
L. Salek (2002)
10.1177/106002809603001204
Effects of Fluvastatin on Hyperlipidemia after Renal Transplantation: Influence of Steroid Therapy
J. Austen (1996)
10.1016/J.AMJCARD.2006.09.117
Comparison of the effects of high doses of rosuvastatin versus atorvastatin on the subpopulations of high-density lipoproteins.
B. Asztalos (2007)
10.2169/INTERNALMEDICINE.48.2645
Rosuvastatin increased serum osteocalcin levels independent of its serum cholesterol-lowering effect in patients with type 2 diabetes and hypercholesterolemia.
I. Kanazawa (2009)
10.3310/HTA11140
A systematic review and economic evaluation of statins for the prevention of coronary events.
S. Ward (2007)
10.1002/14651858.CD003823.pub2
Blood pressure lowering efficacy of angiotensin converting enzyme (ACE) inhibitors for primary hypertension.
Balraj S Heran (2008)
10.1177/039139889702000105
Lipid-Lowering Effects of Fluvastatin in Renal Transplant Patients. A Clinical Observation
S. M. Lal (1997)
10.3949/ccjm.70.6.561
The Lescol Intervention Prevention Study (LIPS): start all patients on statins early after PCI.
A. Messerli (2003)
10.1161/CIRCULATIONAHA.109.900027
Effect of Lipid Lowering With Rosuvastatin on Progression of Aortic Stenosis: Results of the Aortic Stenosis Progression Observation: Measuring Effects of Rosuvastatin (ASTRONOMER) Trial
K. Chan (2010)
10.4065/82.5.543
Achieving low-density lipoprotein cholesterol goals in high-risk patients in managed care: comparison of rosuvastatin, atorvastatin, and simvastatin in the SOLAR trial.
W. Insull (2007)
10.2165/00003495-199400472-00012
Efficacy and Safety of Fluvastatin in Women with Primary Hypercholesterolemia
T. Peters (2012)
10.1016/S0002-9149(03)00006-7
Efficacy of rosuvastatin 10 mg in patients with the metabolic syndrome.
C. Ballantyne (2003)
10.1007/s15010-004-3136-7
Lipid Lowering Therapy with Fluvastatin and Pravastatin in Patients with HIV Infection and Antiretroviral Therapy: Comparison of Efficacy and Interaction with Indinavir
A. Benesic (2004)
10.1016/S0002-9149(05)80013-X
Clinical efficacy of fluvastatin for hyperlipidemia in Japanese patients.
T. Teramoto (1995)
10.1016/J.CLINTHERA.2005.09.012
A cost-effectiveness analysis of fluvastatin in patients with diabetes after successful percutaneous coronary intervention.
P. Scuffham (2005)
10.1016/J.AHJ.2007.03.011
Rationale, design, and baseline characteristics of a randomized trial to assess the effect of cholesterol lowering on the progression of aortic stenosis: the Aortic Stenosis Progression Observation: Measuring Effects of Rosuvastatin (ASTRONOMER) trial.
K. Chan (2007)
10.1016/S0149-2918(03)80285-0
A retrospective analysis of the effect of noncompliance on time to first major adverse cardiac event in LIPS.
E. Lesaffre (2003)
10.1016/j.jacc.2007.11.075
Lipid levels after acute coronary syndromes.
B. Pitt (2008)
10.1007/BF02551424
Fluvastatin (lescol) treatment of hyperlipidaemia in patients with renal transplants
L. Löcsey (2006)
A COMPARISON OF CLINICAL AND PHARMACOECONOMIC PROPERTIES OF FLUVASTATIN AND SIMVASTATIN IN THE MANAGEMENT OF PRIMARY HYPERCHOLESTEROLAEMIA
L. Levin (1997)
Effects of fluvastatin, a new inhibitor of HMG-CoA reductase, and niceritrol on serum lipids, lipoproteins and cholesterol ester transfer activity in primary hypercholesterolemic patients.
J. Sasaki (1995)
10.2478/v10011-008-0028-x
Effect of Conventional and More Aggressive Rosuvastatin Treatment on Markers of Endothelial Activation
A. Postadzhiyan (2008)
10.1038/sj.tpj.6500328
An association study of 43 SNPs in 16 candidate genes with atorvastatin response
J. Thompson (2005)
10.1016/J.AMJCARD.2004.10.008
Long-term fluvastatin reduces the hazardous effect of renal impairment on four-year atherosclerotic outcomes (a LIPS substudy).
P. Lemos (2005)
Effect of diet and treatment with statins on platelet-dependent thrombin generation in hypercholesterolemic subjects.
L. Puccetti (2001)
Comparison of the effects of maximal dose atorvastatin and rosuvastatin therapy on cholesterol synthesis and absorption markers
Thomas M. van Himbergen (2009)
Skin blood flowmotion and microvascular reactivity investigation in hypercholesterolemic patients without clinically manifest arterial diseases.
M. Rossi (2009)
10.1016/J.ATHEROSCLEROSIS.2004.08.033
Fluvastatin and lifestyle modification for reduction of carotid intima-media thickness and left ventricular mass progression in drug-treated hypertensives.
S. Anderssen (2005)
10.1016/S0140-6736(05)67394-1
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.
C. Baigent (2005)
10.1016/S0002-8703(99)70261-9
Long-term safety and efficacy of combination gemfibrozil and HMG-CoA reductase inhibitors for the treatment of mixed lipid disorders.
D. Murdock (1999)
高コレステロール血症患者に対するロスバスタチン 2.5 mg とアトルバスタチン 10 mg の脂質改善効果の比較
悟 角田 (2011)
10.4068/cmj.2013.49.1.31
Rosuvastatin Does Not Affect Fasting Glucose, Insulin Resistance, or Adiponectin in Patients with Mild to Moderate Hypertension
W. Kim (2013)
10.1097/00005344-200005000-00009
Beneficial effects of fluvastatin on myocardial blood flow at two time-points in hypercholesterolemic patients with coronary artery disease.
H. Eichstaedt (2000)
10.1016/S0002-9149(05)80028-1
Effect of fluvastatin for safely lowering atherogenic lipids in renal transplant patients receiving cyclosporine.
H. Holdaas (1995)
10.1016/0002-9343(94)90232-1
Comparison of lipid-lowering effects of low-dose fluvastatin and conventional-dose gemfibrozil in patients with primary hypercholesterolemia.
D. Betteridge (1994)
10.1097/00007890-199612150-00005
Evaluation of fluvastatin in the treatment of hypercholesterolemia in renal transplant recipients taking cyclosporine.
R. Goldberg (1996)
10.1016/J.NUMECD.2006.02.009
Effects of rosuvastatin on 3-nitrotyrosine and aortic stiffness in hypercholesterolemia.
M. Pirro (2007)
10.1007/s002280000254
Effects of fluvastatin on biliary lipids in subjects with an elevated cholesterol saturation index
M. Porsch-Özcürümez (2014)
10.1081/JDI-120039826
Safety and Efficacy of Fluvastatin in Hyperlipidemic Patients With Chronic Renal Disease
G. Yasuda (2004)
10.1016/J.ATHEROSCLEROSIS.2006.11.037
Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study).
J. Mckenney (2007)
10.1210/JC.2002-020370
Effect of fluvastatin slow-release on low density lipoprotein (LDL) subfractions in patients with type 2 diabetes mellitus: baseline LDL profile determines specific mode of action.
K. Winkler (2002)
10.18553/JMCP.2000.6.3.241
Comparative Cost-Effectiveness of Fluvastatin and Lovastatin in Patients with Hypercholesterolemia
D. Hilleman (2015)
Secondary prevention after PCI: the cost-effectiveness of statin therapy in the Netherlands.
S. Chaplin (2004)
10.1016/S0140-6736(03)13638-0
Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial
H. Holdaas (2003)
10.1185/03007991003694498
Cost-effectiveness of rosuvastatin versus ezetimibe/simvastatin in managing dyslipidemic patients in Mexico
Germán Gómez Briseño (2010)
10.1097/00005344-200003000-00003
Efficacy and tolerability of fluvastatin and bezafibrate in patients with hyperlipidemia and persistently high triglyceride levels.
L. Spieker (2000)
10.1016/j.atherosclerosis.2008.11.001
Effects of intensive atorvastatin and rosuvastatin treatment on apolipoprotein B-48 and remnant lipoprotein cholesterol levels.
S. Otokozawa (2009)
10.1016/J.ATHEROSCLEROSIS.2006.11.028
Effect of rosuvastatin 5-20mg on triglycerides and other lipid parameters in Japanese patients with hypertriglyceridemia.
Y. Saitō (2007)
10.1016/J.AMJCARD.2004.09.005
Comparative effects of rosuvastatin and gemfibrozil on glucose, insulin, and lipid metabolism in insulin-resistant, nondiabetic patients with combined dyslipidemia.
C. Lamendola (2005)
10.1093/eurheartj/ehn172
Association of mitral annular calcification and aortic valve morphology: a substudy of the aortic stenosis progression observation measuring effects of rosuvastatin (ASTRONOMER) study.
D. Jassal (2008)
10.1016/S1567-5688(04)90511-4
Cholesterol-lowering effects of rosuvastatin compared with atorvastatin in patients with type 2 diabetes -- CORALL study.
B. Wolffenbuttel (2005)
10.4065/82.7.890
Cellular Telephones and Interference With Privacy–Reply–III
D. Hayes (2007)
Simvastatin compared to fluvastatin in the reduction of serum lipids and apolipoproteins in patients with ischaemic heart disease and moderate hypercholesterolaemia.
G. Sigurdsson (1998)
ATORVASTATIN VS ROSUVASTATIN; FENOFIBRATE AS AN ADD ON: AN EXPLORATORY STUDY
M. A. Khan (2014)
10.1016/0002-9343(94)90235-6
Efficacy and safety of fluvastatin in patients with non-insulin-dependent diabetes mellitus and hyperlipidemia.
R. Knopp (1994)
10.1016/0002-9149(94)90631-9
Efficacy and safety of fluvastatin in patients with non-insulin-dependent diabetes mellitus and hyperlipidemia: preliminary report.
R. Knopp (1994)
10.6452/KJMS.200012.0600
The effect of fluvastatin on fibrinolytic factors in patients with hypercholesterolemia.
T. Lin (2000)
10.1111/J.1523-1755.2004.00919.X
Effect of fluvastatin on renal end points in the Assessment of Lescol in Renal Transplant (ALERT) trial.
B. Fellström (2004)
10.1016/S0002-9149(03)00530-7
Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial).
P. Jones (2003)
[Effect of rosuvastatin therapy and myocardial revascularization on angiogenesis in coronary artery disease patients].
A. Semenova (2007)
10.1185/030079906X132721
Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients*
A. Catapano (2006)
10.1186/1476-511X-6-27
Are HIV positive patients resistant to statin therapy?
K. Johns (2007)
10.1016/J.CLINTHERA.2004.11.001
Efficacy and safety of rosuvastatin alone and in combination with cholestyramine in patients with severe hypercholesterolemia: a randomized, open-label, multicenter trial.
C. Ballantyne (2004)
10.1016/S0002-9149(00)01076-6
Efficacy and safety of an extended-release formulation of fluvastatin for once-daily treatment of primary hypercholesterolemia.
C. Ballantyne (2000)
10.1007/BF02849947
Effects of fluvastatin slow-release (xl 80 mg) versus simvastatin (20 mg) on the lipid triad in patients with type 2 diabetes
M. Bevilacqua (2005)
10.1016/0021-9150(91)90017-W
Effects of fluvastatin (XU 62-320), an HMG-CoA reductase inhibitor, on the distribution and composition of low density lipoprotein subspecies in humans.
J. Yuan (1991)
10.1111/J.1076-7460.2003.02000.X
Short-term efficacy and safety of extended-release fluvastatin in a large cohort of elderly patients.
E. Bruckert (2003)
10.1080/14628840127765
The Lescol ® Intervention Prevention Study (LIPS): a double-blind, placebo-controlled, randomized trial of the long-term effects of fluvastatin after successful transcatheter therapy in patients with coronary heart disease
P. Serruys (2001)
10.1177/0091270006292629
Rosuvastatin Increases α‐1 Microglobulin Urinary Excretion in Patients With Primary Dyslipidemia
M. Kostapanos (2006)
10.1016/S0002-9149(96)00659-5
Meeting national cholesterol education goals in clinical practice--a comparison of lovastatin and fluvastatin in primary prevention.
D. Nash (1996)
10.1186/1471-2296-4-18
Statins in hypercholesterolaemia: A dose-specific meta-analysis of lipid changes in randomised, double blind trials
J. Edwards (2003)
10.2143/AC.64.3.2038029
The influence of rosuvastatin therapy and percutaneous coronary intervention on angiogenic growth factors in coronary artery disease patients
A. Semenova (2009)
10.1016/S0049-3848(99)00037-7
Reduction of platelet activity markers in type II hypercholesterolemic patients by a HMG-CoA-reductase inhibitor.
G. Huhle (1999)
10.1016/j.jacl.2008.10.003
Ezetimibe/simvastatin compared with atorvastatin or rosuvastatin in lowering to specified levels both LDL-C and each of five other emerging risk factors for coronary heart disease: Non-HDL-cholesterol, TC/HDL-C, apolipoprotein B, apo-B/apo-A-I, or C-reactive protein.
M. Davidson (2008)
10.1097/00007890-199811150-00011
Efficacy and muscle safety of fluvastatin in cyclosporine-treated cardiac and renal transplant recipients: an exercise provocation test.
Y. C. Schrama (1998)
10.1177/174182670100800608
Rosuvastatin Demonstrates Greater Reduction of Low-Density Lipoprotein Cholesterol Compared with Pravastatin and Simvastatin in Hypercholesterolaemic Patients: A Randomized, Double-Blind Study
R. Paoletti (2001)
PJ-835 The evaluation of myocardial injury in patients with acute myocardial infarction using 64-slice multi-detector computed tomography(CT / DSA(11)(I),Poster Session(Japanese),The 72nd Annual Scientific Meeting of the Japanese Circulation Society)
K. Kongoji (2008)
10.1016/j.metabol.2010.05.002
Adding exercise to rosuvastatin treatment: influence on C-reactive protein, monocyte toll-like receptor 4 expression, and inflammatory monocyte (CD14+CD16+) population.
P. Coen (2010)
10.1016/J.IJCARD.2006.11.152
The effects of short term statin treatment on left ventricular function and inflammatory markers in patients with chronic heart failure.
C. Gürgün (2008)
10.1016/j.jstrokecerebrovasdis.2014.02.028
Effects of rosuvastatin on serum lipids and arteriosclerosis in dyslipidemic patients with cerebral infarction.
I. Deguchi (2014)
[Fluvastatin in the treatment of hyperlipoproteinemia, initial experience].
R. Češka (1996)
10.1046/j.1365-2362.2002.01086.x
Time‐dependent effect of statins on platelet function in hypercholesterolaemia
L. Puccetti (2002)
10.1111/j.1540-8175.2009.00993.x
Association of Bicuspid Aortic Valve Morphology and Aortic Root Dimensions: A Substudy of the Aortic Stenosis Progression Observation Measuring Effects of Rosuvastatin (ASTRONOMER) Study
D. Jassal (2010)
10.1016/S0002-9149(05)80019-0
Open-label study to assess the efficacy, safety, and tolerability of fluvastatin versus bezafibrate for hypercholesterolemia.
G. Fanghänel (1995)
10.1016/j.jacl.2008.10.001
Long-term safety and efficacy of fenofibric acid in combination with statin therapy for the treatment of patients with mixed dyslipidemia.
H. Bays (2008)
10.1016/j.cjca.2014.03.025
Circulating levels of matrix gla protein and progression of aortic stenosis: a substudy of the Aortic Stenosis Progression Observation: Measuring Effects of rosuvastatin (ASTRONOMER) trial.
R. Capoulade (2014)
10.1016/j.atherosclerosis.2010.12.041
Subtherapeutic, low-dose fluvastatin improves functional and morphological arterial wall properties in apparently healthy, middle-aged males--a pilot study.
M. Lunder (2011)
10.1016/j.numecd.2011.02.009
Increased appearance rate of 27-hydroxycholesterol in vivo in hypercholesterolemia: a possible compensatory mechanism.
M. Bertolotti (2012)
10.1345/aph.1H124
Efficacy and Safety of Rosuvastatin Every Other Day Compared with Once Daily in Patients with Hypercholesterolemia
S. Wongwiwatthananukit (2006)
10.1016/J.ATHEROSCLEROSIS.2004.05.009
The effect of statins and fibrates on interferon-gamma and interleukin-2 release in patients with primary type II dyslipidemia.
B. Okopień (2004)
10.1016/J.AMJCARD.2007.01.028
Comparison of rosuvastatin versus atorvastatin in South-Asian patients at risk of coronary heart disease (from the IRIS Trial).
P. Deedwania (2007)
10.1097/MCA.0b013e32831a8811
Different galenic formulations of fluvastatin have equal lipid-lowering potential but differ in reducing lipemia-induced endothelial dysfunction
S. Westphal (2009)
10.1155/2014/875907
Comparison of Low-Dose Rosuvastatin with Atorvastatin in Lipid-Lowering Efficacy and Safety in a High-Risk Pakistani Cohort: An Open-Label Randomized Trial
A. R. Arshad (2014)
10.1161/01.CIR.99.6.736
Influence of low HDL on progression of coronary artery disease and response to fluvastatin therapy.
C. Ballantyne (1999)
10.2165/00044011-200828100-00003
Evaluation of a New Formulation of Fenofibric Acid, ABT-335,Co-Administered with Statins
P. Jones (2008)
10.1097/QAI.0b013e318160a542
Drug/Drug Interaction Between Lopinavir/Ritonavir and Rosuvastatin in Healthy Volunteers
J. Kiser (2008)
10.1016/j.amjcard.2007.09.099
Efficacy and tolerability of fluvastatin XL 80 mg alone, ezetimibe alone, and the combination of fluvastatin XL 80 mg with ezetimibe in patients with a history of muscle-related side effects with other statins.
E. Stein (2008)
Treatment of patients with mild to moderate hypercholesterolemia: Lipoprotein and Coronary Atherosclerosis Study (LCAS)
C. Ballantyne (1998)
10.1007/s002280050663
Lowering effects of four different statins on serum triglyceride level
A. Branchi (1999)
Effect of simvastatin and fluvastatin on plasma fibrinogen levels in patients with primary hypercholesterolemia.
B. Okopień (2004)
10.1002/14651858.cd010254
Lipid lowering efficacy of rosuvastatin
S. P. Adams (2014)
10.1016/J.AMJCARD.2003.08.076
Effect of fluvastatin on long-term outcome after coronary revascularization with stent implantation.
F. Saia (2004)
10.1515/CCLM.2005.134
Familial hypercholesterolemia and response to statin therapy according to LDLR genetic background
D. Choumerianou (2005)
アトルバスタチンによる冠動脈疾患患者の血管内皮機能と頚動脈内膜中膜肥厚への影響【JST・京大機械翻訳】
Ji Zhen-guo (2008)
[Rosuvastatin and fenofibrate in patients with diabetes and low high density lipoprotein cholesterol: comparison of changes of lipid levels and some markers of inflammation].
Polenova Nv (2009)
10.1016/S0002-9149(01)02226-3
Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia.
M. Davidson (2002)
10.1016/j.clinthera.2013.06.013
A randomized, double-blind study of fenofibric acid plus rosuvastatin compared with rosuvastatin alone in stage 3 chronic kidney disease.
Debra L. Weinstein (2013)
10.1185/030079905X74952
LDL‐C/HDL‐C ratio in subjects with cardiovascular disease and a low HDL‐C: results of the RADAR (Rosuvastatin and Atorvastatin in different Dosages And Reverse cholesterol transport) study
J. Wouter Jukema (2005)
10.1034/j.1399-0004.2001.590604.x
LDL‐receptor gene mutations and the hypocholesterolemic response to statin therapy
J. U. Brorholt-Petersen (2001)
10.1016/j.jacc.2009.11.083
Metabolic syndrome is associated with more pronounced impairment of left ventricle geometry and function in patients with calcific aortic stenosis: a substudy of the ASTRONOMER (Aortic Stenosis Progression Observation Measuring Effects of Rosuvastatin).
A. Pagé (2010)
10.3904/kjim.2010.25.1.27
Comparative Study of Low Doses of Rosuvastatin and Atorvastatin on Lipid and Glycemic Control in Patients with Metabolic Syndrome and Hypercholesterolemia
J. Park (2010)
10.1016/j.amjcard.2011.12.015
Comparison of lipid-modifying efficacy of rosuvastatin versus atorvastatin in patients with acute coronary syndrome (from the LUNAR study).
B. Pitt (2012)
10.2169/INTERNALMEDICINE.50.4059
Potential benefit of statin therapy for dyslipidemia with chronic kidney disease: Fluvastatin Renal Evaluation Trial (FRET).
T. Inoue (2011)
10.1097/00019501-199809090-00005
Elderly patients with hypercholesterolaemia: a double‐blind study of the efficacy, safety and tolerability of fluvastatin
M. Lye (1998)
10.1016/J.IJCARD.2004.12.011
Effects of switching statins on lipid and apolipoprotein ratios in the MERCURY I study.
R. Cheung (2005)
10.1016/j.ijcard.2011.11.028
Differential metabolic effects of rosuvastatin and pravastatin in hypercholesterolemic patients.
K. Koh (2013)
10.1016/J.EBCM.2006.04.017
Rosuvastatin may be more effective than atorvastatin in African-Americans with hypercholesterolemia.
F. Fonseca (2006)
10.1111/j.1464-5491.2007.02095.x
Effects of rosuvastatin on lipids, lipoproteins and apolipoproteins in the dyslipidaemia of diabetes
D. Betteridge (2007)
10.1016/S0021-9150(96)05972-2
Reduced susceptibility of low density lipoprotein (LDL) to lipid peroxidation after fluvastatin therapy is associated with the hypocholesterolemic effect of the drug and its binding to the LDL.
O. Hussein (1997)
10.1016/S0002-9149(03)00318-7
Beneficial effects of rosuvastatin alone and in combination with extended-release niacin in patients with a combined hyperlipidemia and low high-density lipoprotein cholesterol levels.
D. Capuzzi (2003)
10.1586/14737167.5.2.113
Use of fluvastatin following percutaneous coronary intervention
P. Scuffham (2005)
10.1016/J.IJCARD.2003.11.031
Fluvastatin reduces the 4-year cardiac risk in patients with multivessel disease.
P. Lemos (2005)
10.1007/BF00315307
Efficacy and safety of high dose fluvastatin in patients with familial hypercholesterolaemia
E. Leitersdorf (2004)
10.1111/j.1365-2125.2008.03213.x
The human paraoxonase-1 phenotype modifies the effect of statins on paraoxonase activity and lipid parameters.
H. Z. Mirdamadi (2008)
10.1089/met.2009.0009
Low-density lipoprotein cholesterol reduction and goal achievement with ezetimibe/simvastatin versus atorvastatin or rosuvastatin in patients with diabetes, metabolic syndrome, or neither disease, stratified by National Cholesterol Education Program risk category.
A. Polis (2009)
10.1038/SJ.KI.5000327
Effect of fluvastatin on apolipoprotein-defined lipoprotein subclasses in patients with chronic renal insufficiency.
P. Alaupovic (2006)
10.1161/HH0901.090301
Novel Polymorphisms in Promoter Region of ATP Binding Cassette Transporter Gene and Plasma Lipids, Severity, Progression, and Regression of Coronary Atherosclerosis and Response to Therapy
S. Lutucuta (2001)
10.2165/00019053-200422080-00004
An Economic Evaluation of Fluvastatin used for the Prevention of Cardiac Events Following Successful First Percutaneous Coronary Intervention in the UK
P. Scuffham (2012)
10.1016/J.AHJ.2004.01.020
Efficacy and safety of rosuvastatin and atorvastatin in patients with hypercholesterolemia and a high risk of coronary heart disease: a randomized, controlled trial.
G. Schwartz (2004)
10.1016/j.atherosclerosis.2009.11.021
Early vascular and metabolic effects of rosuvastatin compared with simvastatin in patients with type 2 diabetes.
A. Bellia (2010)
10.1067/MHJ.2002.128049
Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia.
A. Olsson (2002)
10.1016/j.jacc.2009.10.042
Efficacy and safety of rosuvastatin therapy for children with familial hypercholesterolemia.
H. Avis (2010)
10.2174/1381612820666140127163313
Anti-inflammatory effects of rosuvastatin in healthy subjects: a prospective longitudinal study.
T. Mcguire (2014)
10.1016/j.curtheres.2006.02.005
Rosuvastatin versus atorvastatin in achieving lipid goals in patients at high risk for cardiovascular disease in clinical practice: A randomized, open-label, parallel-group, multicenter study (DISCOVERY Alpha study).
A. Binbrek (2006)
Effect of fluvastatin or bezafibrate on the distribution of high density lipoprotein subpopulations in patients with familial hypercholesterolemia.
S. Hailer (1996)
Fluvastatin reduces oxidative stress, decreases serum monocyte chemotactic protein-1 level and improves endothelial function in patients with hypercholesterolemia.
Hsin‐Bang Leu (2004)
10.1016/0002-9149(94)90627-0
Clinical implications of the biopharmaceutical properties of fluvastatin.
J. Deslypere (1994)
10.1016/0002-9343(94)90229-1
Fluvastatin reduces levels of plasma apo B-containing particles and increases those of LpA-I. European Fluvastatin Study Group.
J. Dallongeville (1994)
10.2165/11533430-000000000-00000
Efficacy and Safety of Rosuvastatin and Fenofibric Acid Combination Therapy versus Simvastatin Monotherapy in Patients with Hypercholesterolemia and Hypertriglyceridemia
Eli M. Roth (2010)
10.3760/CMA.J.ISSN.0376-2491.2014.31.015
[Effects of rosuvastatin on arterial stiffness in hyperlipidemia patients].
P. Wang (2014)
10.1016/J.AMJCARD.2007.05.044
Comparison of effectiveness of rosuvastatin versus atorvastatin on the achievement of combined C-reactive protein (<2 mg/L) and low-density lipoprotein cholesterol (< 70 mg/dl) targets in patients with type 2 diabetes mellitus (from the ANDROMEDA study).
D. Betteridge (2007)
Right bundle branch block, persistent ST-segment elevation, and sudden death.
RuDusky Bm (1998)
Cost effectiveness of HMG-CoA reductase inhibition in Canada.
M. W. Russell (2001)
The effect of fluvastatin on cICAM-1 as a biomarker of endothelial dysfunction in patients with dyslipidemia.
T. Šejda (2006)
10.1016/j.jacl.2007.07.004
Comparison of short-term renal effects and efficacy of rosuvastatin 40 mg and simvastatin 80 mg, followed by assessment of long-term renal effects of rosuvastatin 40 mg, in patients with dyslipidemia.
Evan A. Stein (2007)
10.1210/JC.2003-031494
Fluvastatin slow-release lowers platelet-activating factor acetyl hydrolase activity: a placebo-controlled trial in patients with type 2 diabetes.
K. Winkler (2004)
10.1001/JAMA.287.24.3215
Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial.
P. Serruys (2002)
10.1536/IHJ.13-216
Change in carotid intima-media thickness in a high-risk group of patients by intensive lipid-lowering therapy with rosuvastatin: subanalysis of the JART study.
H. Yokoi (2014)
10.1507/ENDOCRJ.52.259
Anti-oxidative effect of fluvastatin in hyperlipidemic type 2 diabetic patients.
Shinnya Miwa (2005)
[The efficacy and safety of rosuvastatin on treating patients with hypercholesterolemia in Chinese: a randomized, double-blind, multi-center clinical trial].
R. Gao (2007)
[Long-term treatment of combined hyperlipidemia with a combination of fluvastatin and fenofibrate].
J. Widimský (1999)
10.1161/01.CIR.0000133317.49796.0E
Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines
S. Grundy (2004)
10.1016/j.echo.2008.02.014
Clinical usefulness of tissue Doppler imaging in patients with mild to moderate aortic stenosis: a substudy of the aortic stenosis progression observation measuring effects of rosuvastatin study.
D. Jassal (2008)
10.1016/S1726-4901(09)70175-3
Efficacy and Safety of Slow‐release Fluvastatin 80 mg Daily in Chinese Patients with Hypercholesterolemia
Chih-Cheng Wu (2005)
10.1016/J.AMJCARD.2006.10.022
Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study).
C. Ballantyne (2007)
10.1016/0026-0495(95)90145-0
Comparison of the effect of fluvastatin, an hydroxymethyl glutaryl coenzyme A reductase inhibitor, and cholestyramine, a bile acid sequestrant, on lipoprotein particles defined by apolipoprotein composition.
J. M. Bard (1995)
10.1111/liv.12316
Omega‐3 fatty acids and/or fluvastatin in hepatitis C prior non‐responders to combination antiviral therapy – a pilot randomised clinical trial
D. Sheridan (2014)
10.1046/J.1365-2125.1997.00625.X
Reduced platelet aggregation after fluvastatin therapy is associated with altered platelet lipid composition and drug binding to the platelets.
H. Osamah (1997)
10.1016/S0002-9149(96)00221-4
Relation between perfusion defects on stress technetium-99m sestamibi SPECT scintigraphy and the location of a subsequent acute myocardial infarction.
G. Miller (1996)
10.1177/0300060513507648
Efficacy of low-dose rosuvastatin in patients with type 2 diabetes and hypo high-density lipoprotein cholesterolaemia
T. Katabami (2014)
10.1016/j.ejphar.2008.06.007
Baseline triglyceride levels and insulin sensitivity are major determinants of the increase of LDL particle size and buoyancy induced by rosuvastatin treatment in patients with primary hyperlipidemia.
M. Kostapanos (2008)
A COMPARISON BETWEEN FLUVASTATIN AND LOVASTATIN EFFECTS IN IRANIAN PATIENTS WITH HYPERCHOLESTEROLEMIA
S. Moradm (1998)
10.1016/j.amjcard.2010.09.031
Effects of maximal atorvastatin and rosuvastatin treatment on markers of glucose homeostasis and inflammation.
Nuntakorn Thongtang (2011)
10.1097/00005344-200207000-00004
Valsartan Therapy Has Additive Anti-oxidative Effect to That of Fluvastatin Therapy Against Low-Density Lipoprotein Oxidation: Studies in Hypercholesterolemic and Hypertensive Patients
O. Hussein (2002)
10.1590/S0066-782X2012005000096
Rosuvastatin and ciprofibrate in the treatment of dyslipidemia in patients with HIV.
H. Domingos (2012)
10.1016/J.AMJCARD.2006.04.014
Comparison of rosuvastatin versus atorvastatin in Hispanic-Americans with hypercholesterolemia (from the STARSHIP trial).
R. Lloret (2006)
10.1177/147323000203000104
Effects of Fluvastatin Treatment on Insulin Sensitivity in Patients with Hyperlipidaemia
BY Cingözbay (2002)
10.1089/met.2012.0103
Colesevelam plus rosuvastatin 5 mg/day versus rosuvastatin 10 mg/day alone on markers of insulin resistance in patients with hypercholesterolemia and impaired fasting glucose.
M. Florentin (2013)
10.1097/SMJ.0b013e31819bd023
Effects of Rosuvastatin and Colestimide on Metabolic Parameters and Urinary Monocyte Chemoattractant Protein-1 in Type 2 Diabetic Patients with Hyperlipidemia
K. Takebayashi (2009)
10.2165/00044011-200121020-00003
Comparison of the Efficacy, Safety and Tolerability of Policosanol versus Fluvastatin in Elderly Hypercholesterolaemic Women
J. Fernández (2001)
10.1007/s10557-006-8877-3
The Cost-Effectiveness of Fluvastatin in Hungary Following Successful Percutaneous Coronary Intervention
P. A. Scuffham (2006)
[Effect of therapy with rosuvastatin on lipid spectrum, factors of inflammation and endothelial function in patients with ischemic heart disease].
I. Sergienko (2006)
10.1016/S0021-9150(02)00149-1
Comparing the effects of five different statins on the HDL subpopulation profiles of coronary heart disease patients.
B. Asztalos (2002)
10.1016/S0049-3848(97)00143-6
Fluvastatin and tissue factor pathway inhibitor in type IIA and IIB hyperlipidemia and in acute myocardial infarction.
M. Lorena (1997)
A FLUVASTATIN HATASA A SZERUM LIPID SZINTEKRE ESSZENCIALIS HIPERTONIAS BETEGEKBEN
Z. Járai (1996)
10.1016/S0002-9149(05)80034-7
Treatment of combined hyperlipidemia with fluvastatin and gemfibrozil, alone or in combination, does not induce muscle damage.
J. Smit (1995)
10.1111/j.1365-2710.2010.01161.x
Inhibition of intestinal cholesterol absorption might explain cholesterol‐lowering effect of telmisartan
T. Inoue (2011)
10.1016/J.AMJCARD.2004.03.052
Effect of rosuvastatin on plasma levels of asymmetric dimethylarginine in patients with hypercholesterolemia.
T. Lu (2004)
10.1002/CLC.4960280907
Effects of fluvastatin, an HMG‐CoA reductase inhibitor, on serum levels of interleukin‐18 and matrix metalloproteinase‐9 in patients with hypercholesterolemia
Hsin‐Bang Leu (2005)
Efficacy and safety of rosuvastatin in the treatment of hypercholesterolemia
Zhao Rui-ping (2013)
10.1177/14746514060060040501
The MERCURY II trial: benefits of rosuvastatin
L. Izzat (2006)
10.1016/S0021-9150(99)00004-0
Lipoprotein lipase gene mutations, plasma lipid levels, progression/regression of coronary atherosclerosis, response to therapy, and future clinical events. Lipoproteins and Coronary Atherosclerosis Study.
K. Sing (1999)
10.1016/j.metabol.2009.03.006
Adding exercise training to rosuvastatin treatment: influence on serum lipids and biomarkers of muscle and liver damage.
P. Coen (2009)
10.1007/s002280050338
Effects of fluvastatin therapy on lipids, antioxidants, oxidation of low density lipoproteins and trace metals
W. Leonhardt (1997)
10.1185/03007995.2013.766590
A double-blind, double-dummy, randomized, placebo-controlled trial to evaluate the effect of statin therapy on triglyceride levels in Mexican hypertriglyceridemic patients
Juan-Osvaldo Talavera (2013)
10.1016/j.amjcard.2012.10.037
Alteration of relation of atherogenic lipoprotein cholesterol to apolipoprotein B by intensive statin therapy in patients with acute coronary syndrome (from the Limiting UNdertreatment of lipids in ACS With Rosuvastatin [LUNAR] Trial).
C. Ballantyne (2013)
10.2165/00003495-199400472-00010
Gender-Related Response to Fluvastatin in Patients with Heterozygous Familial Hypercholesterolaemia
E. Leitersdorf (2012)
10.1067/MHJ.2002.129312
Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: a randomized, double-blind, 52-week trial.
W. Brown (2002)
10.1016/S0002-9149(97)00346-9
Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS]).
J. Herd (1997)
10.1080/09537100701230444
The effect of rosuvastatin treatment on the mean platelet volume in patients with uncontrolled primary dyslipidemia with hypolipidemic diet treatment
E. Coban (2008)
10.1016/j.linthera.2008.01.013
Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: a 12-week, multicenter, randomized, open-label, parallel-group study.
L. Álvarez-Sala (2008)
10.1185/030079903125002405
Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial
J. Mckenney (2003)
10.1586/14779072.2014.942640
Addition of omega-3 carboxylic acids to statin therapy in patients with persistent hypertriglyceridemia
M. Davidson (2014)
10.1016/S0002-9149(05)80029-3
A preliminary report of the safety and efficacy of fluvastatin for hypercholesterolemia in renal transplant patients receiving cyclosporine.
R. Goldberg (1995)
10.1016/S0002-9149(05)80025-6
Efficacy and safety of triple therapy (fluvastatin-bezafibrate-cholestyramine) for severe familial hypercholesterolemia.
E. Leitersdorf (1995)
10.1093/OXFORDJOURNALS.EURHEARTJ.A015257
Management of hyperlipidaemia. Why, when and how to treat.
M. Oliver (1997)
10.1016/j.ijcard.2013.08.125
Bergamot polyphenolic fraction enhances rosuvastatin-induced effect on LDL-cholesterol, LOX-1 expression and protein kinase B phosphorylation in patients with hyperlipidemia.
M. Gliozzi (2013)
10.1177/1358836X9900400405
Lipid-lowering and skin vascular responses in patients with hypercholesterolaemia and peripheral arterial obstructive disease
F. Khan (1999)
10.1016/J.AMJCARD.2003.08.009
Comparison of rosuvastatin versus atorvastatin in patients with heterozygous familial hypercholesterolemia.
E. Stein (2003)
10.1016/J.AMJCARD.2007.06.029
Long-term efficacy and safety of rosuvastatin 40 mg in patients with severe hypercholesterolemia.
E. Stein (2007)
10.1016/J.AMJCARD.2004.02.046
Effect of fluvastatin therapy on coronary flow reserve in patients with hypercholesterolemia.
Kohei Fujimoto (2004)
10.1016/J.CLINTHERA.2004.09.006
Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial.
P. Jones (2004)
10.1185/030079904X4167
Lipid-modifying effects of rosuvastatin in postmenopausal women with hypercholesterolemia who are receiving hormone replacement therapy*
J. Shepherd (2004)
10.1177/1074248412445506
Effects of Rosuvastatin With or Without Ezetimibe on Clinical Outcomes in Patients Undergoing Elective Vascular Surgery
G. Kouvelos (2013)
10.1177/14746514080080030601
The MERCURY I open-label extension study — subgroup analysis in patients with diabetes:
H. Schuster (2008)
10.1016/J.DIABRES.2003.11.012
Rosuvastatin and fenofibrate alone and in combination in type 2 diabetes patients with combined hyperlipidaemia.
P. Durrington (2004)
10.1016/S0953-6205(01)00172-8
Secondary prevention with fluvastatin decreases levels of adhesion molecules, neopterin and C-reactive protein.
P. L. van Haelst (2001)
Chapter 8: Assessing risk of bias in included studies
J. P. Higgins (2008)
10.1007/s13340-012-0103-x
Effects of pravastatin, atorvastatin, and rosuvastatin in patients with type 2 diabetes mellitus and hypercholesterolemia
H. Mori (2013)
The effect of a new hypolipemic preparation fluvastatin (Lescol) on rheological indices and hemostatic parameters
Filippova Vg (1997)
10.1089/aid.2012.0015
Two-year treatment with rosuvastatin reduces carotid intima-media thickness in HIV type 1-infected patients receiving highly active antiretroviral therapy with asymptomatic atherosclerosis and moderate cardiovascular risk.
L. Calza (2013)
10.1016/S0002-9343(01)00679-9
Effects of 1-year treatment with fluvastatin or pravastatin on bone.
S. Watanabe (2001)
10.1016/j.jpeds.2010.08.015
Rosuvastatin lowers coenzyme Q10 levels, but not mitochondrial adenosine triphosphate synthesis, in children with familial hypercholesterolemia.
H. Avis (2011)
Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)
J. Pincus (1998)
Drug Class Review: HMG-CoA Reductase Inhibitors (Statins) and Fixed-dose Combination Products Containing a Statin
M. Smith (2009)
10.1097/01.fjc.0000246150.52382.07
Neutrophil Superoxide Anion Generation During Atorvastatin and Fluvastatin Therapy Used in Coronary Heart Disease Primary Prevention
J. Kowalski (2006)
10.1016/S0002-9149(05)80018-9
Comparison of fluvastatin versus pravastatin treatment of primary hypercholesterolemia. French Fluvastatin Study Group.
B. Jacotot (1995)
10.1185/030079907X226104
Effect of rosuvastatin versus atorvastatin treatment on paraoxonase-1 activity in men with established cardiovascular disease and a low HDL-cholesterol
S. Bergheanu (2007)
10.13181/MJI.V17I2.309
Safety and tolerability of fluvastatin XL in the treatment of hyper-cholesterolemia : a postmarketing surveillance conducted in Indonesia
A. Setiawati (2008)
10.1016/j.jacc.2012.03.052
Impact of metabolic syndrome on progression of aortic stenosis: influence of age and statin therapy.
R. Capoulade (2012)
10.1253/CIRCJ.CJ-11-0887
Effect of intensive lipid-lowering therapy with rosuvastatin on progression of carotid intima-media thickness in Japanese patients: Justification for Atherosclerosis Regression Treatment (JART) study.
R. Nohara (2012)
10.1016/0753-3322(96)84824-4
Effects of two different HMG-CoA reductase inhibitors on thromboxane production in type IIA hypercholesterolemia.
M. Milani (1996)
10.2337/DC08-1681
Effects of Rosuvastatin and Atorvastatin on Low-Density and High-Density Lipoprotein Particle Concentrations in Patients With Metabolic Syndrome: A Randomized, Double-Blind, Controlled Study
R. Rosenson (2009)
10.1111/j.1755-5922.2010.00141.x
STATIN-D study: comparison of the influences of rosuvastatin and fluvastatin treatment on the levels of 25 hydroxyvitamin D.
D. Ertuğrul (2011)
10.1007/BF03261902
Predictive Value of the Low-Density Lipoprotein Cholesterol to High-Density Lipoprotein Cholesterol Ratio for the Prevention of Stroke Recurrence in Japanese Patients Treated with Rosuvastatin
M. Igase (2012)
10.5551/JAT.1438
Evaluation of plaque stabilization by fluvastatin with carotid intima- medial elasticity measured by a transcutaneous ultrasonic-based tissue characterization system.
T. Yamagishi (2009)
10.2165/00007256-199927050-00004
Effect of Fluvastatin in Combination with Moderate Endurance Training on Parameters of Lipid Metabolism
R. Wittke (1999)
10.1016/J.JCLINEPI.2005.06.006
Imputing missing standard deviations in meta-analyses can provide accurate results.
T. Furukawa (2006)
10.1016/J.AHJ.2005.12.013
Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY (MERCURY) II.
C. Ballantyne (2006)
10.2174/1874192401408010055
Comparative Effect of Atorvastatin and Rosuvastatin on 25-hydroxy-Vitamin D Levels in Non-diabetic Patients with Dyslipidaemia: A Prospective Randomized Open-label Pilot Study
P. Anagnostis (2014)
10.1385/ENDO:22:2:151
Fluvastatin improves insulin resistance in nondiabetic dyslpidemic patients
A. Sonmez (2007)
10.1177/1074248408331021
Influence of Short-term Rosuvastatin Therapy on Endothelial Progenitor Cells and Endothelial Function
M. Pirro (2009)
10.1016/S0024-3205(99)00199-X
Clinical pharmacology of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors.
M. Moghadasian (1999)
10.1016/S0735-1097(99)00535-5
Interactions between angiotensin-I converting enzyme insertion/deletion polymorphism and response of plasma lipids and coronary atherosclerosis to treatment with fluvastatin: the lipoprotein and coronary atherosclerosis study.
A. Marian (2000)
10.1556/OH.2012.29390
[Effectiveness of generic rosuvastatin in patients with ischaemic cerebrovascular disease].
L. Szapáry (2012)
10.1016/S0002-9149(05)80036-0
Effects of fluvastatin on lipid profile and apolipoproteins in Chinese patients with hypercholesterolemia.
B. Tomlinson (1995)
10.1001/ARCHINTE.154.21.2449
Efficacy and safety of once-daily vs twice-daily dosing with fluvastatin, a synthetic reductase inhibitor, in primary hypercholesterolemia.
W. Insull (1994)
10.1016/0002-9343(94)90234-8
Fluvastatin and niacin in hypercholesterolemia: a preliminary report on gender differences in efficacy.
T. Jacobson (1994)
10.1016/0002-9149(94)90632-7
Baseline characteristics of subjects in the Lipoprotein and Coronary Atherosclerosis Study (LCAS) with fluvastatin.
J. Herd (1994)
10.1253/CIRCJ.CJ-12-1149
Effect of long-term intensive lipid-lowering therapy with rosuvastatin on progression of carotid intima-media thickness--Justification for Atherosclerosis Regression Treatment (JART) extension study.
R. Nohara (2013)
10.1177/0003319708316005
Fluvastatin Treatment and Withdrawal: Effects on Endothelial Function
S. Westphal (2008)
10.1016/S0041-1345(99)00362-0
Fluvastatin in the treatment of hypercholesterolemia in renal transplantation.
G. Gómez (1999)
10.1097/00008571-200401000-00007
Effects of PPARalpha, gamma and delta haplotypes on plasma levels of lipids, severity and progression of coronary atherosclerosis and response to statin therapy in the lipoprotein coronary atherosclerosis study.
S. Chen (2004)
10.1159/000082166
Treatment with Fluvastatin Rapidly Modulates, via Different Pathways, and in Dependence on the Baseline Level, Inflammation in Hemodialysis Patients
G. Tsirpanlis (2004)
10.1080/08035250600702602
Efficacy and safety of fluvastatin in children and adolescents with heterozygous familial hypercholesterolaemia
Anouk van der Graaf (2006)
10.1016/S0197-2456(96)00178-X
The Lipoprotein and Coronary Atherosclerosis Study (LCAS): design, methods, and baseline data of a trial of fluvastatin in patients without severe hypercholesterolemia.
Michael S West (1996)
Extended-release fluvastatin 80 mg shows greater efficacy, with comparable tolerability, versus immediate-release fluvastatin 40 mg for once daily treatment of primary hypercholesterolaemia
D. Hunninghake (2002)
10.1097/MCA.0000000000000054
Effects of combination of statin and calcium channel blocker in patients with cardiac syndrome X
Xinling Zhang (2014)
10.7326/0003-4819-122-9-199505010-00006
Effects of Alcohol and Fluvastatin on Lipid Metabolism and Hepatic Function
J. Smit (1995)
10.1177/1074248409357922
Effects of Atorvastatin 20 mg, Rosuvastatin 10 mg, and Atorvastatin/Ezetimibe 5 mg/5 mg on Lipoproteins and Glucose Metabolism
A. Her (2010)
10.1001/jama.1993.03500230097036
Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)
S. Grundy (1993)
10.1592/PHCO.25.2.270.56946
Cost-efficacy analysis of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors based on results of the STELLAR trial: clinical implications for therapeutic selection.
P. Chong (2005)
10.1016/J.METABOL.2005.03.021
Angiotensin II-induced oxidative burst is fluvastatin sensitive in neutrophils of patients with hypercholesterolemia.
I. Seres (2005)
10.1016/S0041-1345(96)00646-X
Treatment of metabolic disorders with fluvastatin after renal transplantation.
H. Podder (1997)
10.1185/030079905X56529
The DISCOVERY PENTA study: a DIrect Statin COmparison of LDL‐C Value – an Evaluation of Rosuvastatin therapY compared with atorvastatin*
F. Fonseca (2005)
Treating to meet NCEP-recommended LDL cholesterol concentrations with atorvastatin, fluvastatin, lovastatin, or simvastatin in patients with risk factors for coronary heart disease.
D. Hunninghake (1998)
10.4103/2230-8210.111644
Dyslipidemic drugs in metabolic syndrome
S. S. Siddiqi (2013)
10.1177/107424849600100105
A Randomized Multicenter Trial Comparing the Efficacy of Simvastatin and Fluvastatin
D. D. Illingworth (1996)
Fluvastatin reduces soluble P-selectin and ICAM-1 levels in hypercholesterolemic patients: role of nitric oxide.
M. Romano (2000)
10.1016/S0002-9149(97)00965-X
Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)
P. Jones (1998)
10.1016/S0002-9149(01)01638-1
Correlation of non-high-density lipoprotein cholesterol with apolipoprotein B: effect of 5 hydroxymethylglutaryl coenzyme A reductase inhibitors on non-high-density lipoprotein cholesterol levels.
C. Ballantyne (2001)
10.1016/S1567-5688(01)80029-5
Rosuvastatin is more effective than atorvastatin at improving the lipid profiles of patients with primary hypercholesterolaemia
M. Davidson (2001)
10.1016/0002-9149(94)90088-4
Fluvastatin with and without niacin for hypercholesterolemia.
T. Jacobson (1994)
10.1111/j.1464-5491.2011.03553.x
Effects of rosuvastatin and atorvastatin on glycaemic control in Type 2 diabetes—the CORALL study
S. Simsek (2012)
10.1002/14651858.CD009462.PUB2
Chronotherapy versus conventional statins therapy for the treatment of hyperlipidaemia.
J. M. Izquierdo-Palomares (2016)
10.1016/j.ahj.2011.03.016
Effect of rosuvastatin on C-reactive protein and progression of aortic stenosis.
K. Chan (2011)
10.1161/01.HYP.0000221223.23028.f1
Effect of Low-Density Lipoprotein Cholesterol on Angiotensin II Sensitivity: A Randomized Trial With Fluvastatin
N. A. J. van der Linde (2006)
10.1310/hct1303-153
Statin Therapy Decreases Serum Levels of High-Sensitivity C-Reactive Protein and Tumor Necrosis Factor-α in HIV-Infected Patients Treated With Ritonavir-Boosted Protease Inhibitors
L. Calza (2012)
10.1016/j.atherosclerosis.2010.11.002
Effects of rosuvastatin and allopurinol on circulating endothelial progenitor cells in patients with congestive heart failure: the impact of inflammatory process and oxidative stress.
D. Tousoulis (2011)
[Effect of statin therapy on dynamics of vascular endothelial growth factor and fibroblast growth factor in patients with ischemic heart disease].
I. Sergienko (2007)
10.1053/AJKD.2002.29883
Fluvastatin improves lipid abnormalities in patients with moderate to advanced chronic renal insufficiency.
O. Samuelsson (2002)
10.1016/j.jacc.2008.08.039
Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients.
E. Mills (2008)
10.2741/E577
Rosuvastatin effect on intima media thickness in adult vs elderly patients.
G. Riccioni (2012)
10.1055/S-0037-1613755
Fluvastatin decreases soluble thrombomodulin in cardiac transplant recipients.
P. Ambrosi (2000)
Plasma lipids and blood fluidity in patients with polygenic hypercholesterolaemia treated with fluvastatin.
F. Piñón (2002)
10.1097/00045391-199809000-00002
Fluvastatin Titrate‐to‐Goal Clinical Practice Study
R. Weiss (1998)
10.1016/S0149-2918(03)80113-3
Comparison of treatment with fluvastatin extended-release 80-mg tablets and immediate-release 40-mg capsules in patients with primary hypercholesterolemia.
J. Isaacsohn (2003)
[Hypotensive effect of an inhibitor of cholesterol synthesis (fluvastatin). A pilot study].
G. Abetel (1998)
FOCUS ON ATORVASTATIN : AN HMG-COA REDUCTASE INHIBITOR FOR LOWERING BOTH ELEVATED LDL CHOLESTEROL AND TRIGLYCERIDES IN HYPERCHOLESTEROLEMIC PATIENTS
K. Kellick (1997)
10.2165/00044011-200121100-00001
Treatment of Dyslipidaemia with Fluvastatin in Patients with Type 2 Diabetes Mellitus
F. Visseren (2001)
10.1111/j.1742-1241.2011.02779.x
Comparison of the effects of simvastatin vs. rosuvastatin vs. simvastatin/ezetimibe on parameters of insulin resistance
E. Moutzouri (2011)
10.1161/ATVBAHA.106.128793
Fluvastatin Alters Platelet Aggregability in Patients With Hypercholesterolemia: Possible Improvement of Intraplatelet Redox Imbalance via HMG-CoA Reductase
N. Haramaki (2007)
10.1097/00007890-199510150-00006
Effect of fluvastatin on lipoprotein profiles in treating renal transplant recipients with dyslipoproteinemia.
P. Li (1995)
10.1016/S0002-9149(05)80035-9
Effect of fluvastatin on intermediatedensity Lipoprotein (remnants) and other lipoprotein levels in hypercholestarolemia
F. E. Broyles (1995)
10.1007/BF00191909
Fluvastatin efficacy and tolerability in comparison and in combination with cholestyramine
E. Hagen (2004)
Rosuvastatin in hemodialysis: short-term effects on lipids and C-reactive protein.
J. E. Burmeister (2009)
10.2165/00044011-199918030-00005
Comparison of the Lipid-Lowering Effects of Fluvastatin, Lovastatin and Simvastatin in Patients with Hyperlipoproteinaemia
G. Paragh (1999)
10.1023/A:1015052312866
The effect of fluvastatin of hyperlipidemia in renal transplant recipients: A prospective, placebo- controlled study
S. Türk (2004)
10.1016/S0041-1345(01)01966-2
Efficacy and safety of treatment with low-dose fluvastatin in hypercholesterolemic renal transplant recipients.
T. Akiyama (2001)
10.1016/S0002-9149(01)01486-2
Plasma vascular endothelial growth factor and its receptor Flt-1 in patients with hyperlipidemia and atherosclerosis and the effects of fluvastatin or fenofibrate.
A. Blann (2001)
10.1159/000127442
Efficacy and Tolerability of Rosuvastatin and Atorvastatin when Force-Titrated in Patients with Primary Hypercholesterolemia
O. Faergeman (2008)
[EFFECT OF ASCORBIC ACID ON THE DISTRIBUTION OF 4-C-14-CHOLESTEROL IN TISSUES IN EXPERIMENTAL ATHEROSCLEROSIS].
Zaĭtsev Vf (1964)
[Factors associated with low ankle-brachial index in patients with type 2 diabetes and prediabetes].
Polenova Nv (2009)
Saudi Arabia experience trial of fluvastatin (Lescol) in the treatment of hyperlipidemia.
Galal Ms (1997)
10.1161/01.CIR.103.15.1942
Fluvastatin Lowers Atherogenic Dense Low-Density Lipoproteins in Postmenopausal Women With the Atherogenic Lipoprotein Phenotype
W. Maerz (2001)
10.4236/PP.2012.31011
Rosuvastatin Reduces Plasma Small Dense LDL-Cholesterol Predominantly in Non-Diabetic Hypercholesterolemic Patients
G. Yoshino (2012)
10.1177/1074248408331031
Dose-dependent Effect of Rosuvastatin Treatment on HDL-subfraction Phenotype in Patients With Primary Hyperlipidemia
M. Kostapanos (2009)
10.5551/JAT.10.329
Randomized dose-response study of rosuvastatin in Japanese patients with hypercholesterolemia.
Y. Saitō (2003)
10.1097/gme.0b013e318259c04e
Low-dose rosuvastatin improves the functional and morphological markers of atherosclerosis in asymptomatic postmenopausal women with dyslipidemia
M. Igase (2012)
10.1016/S1520-765X(03)90032-0
Apolipoproteins: the new prognostic indicator?
C. Packard (2003)
Anti-sympathetic action enhances statin's pleiotropic effects: the combined effect of rosuvastatin and atenolol on endothelial function.
B. Takase (2014)
10.1007/s11745-011-3538-0
High Doses of Rosuvastatin are Superior to Low Doses of Rosuvastatin Plus Fenofibrate or n-3 Fatty Acids in Mixed Dyslipidemia
A. Agouridis (2011)
10.1111/j.1365-2796.2005.01499.x
Cholesterol‐lowering effects of rosuvastatin compared with atorvastatin in patients with type 2 diabetes – CORALL study
B. Wolffenbuttel (2005)
10.1159/000177324
Efficacy and safety of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fluvastatin in hyperlipidemic patients treated with probucol.
S. Sasaki (1997)
10.1016/S0002-9149(05)80030-X
Effects of fluvastatin on humanbiliary lipids
S. Tazuma (1995)
10.1111/J.1365-2125.1994.TB04350.X
Efficacy of a low dose-range of fluvastatin (XU 62-320) in the treatment of primary hypercholesterolaemia. A dose-response study in 431 patients. The French-Dutch Fluvastatin Study Group.
B. Jacotot (1994)
10.1136/hrt.2003.027284
Beneficial effects of fluvastatin following percutaneous coronary intervention in patients with unstable and stable angina: results from the Lescol intervention prevention study (LIPS)
C. H. Lee (2004)
10.1185/03007995.2010.509264
Effect of increasing doses of Rosuvastatin and Atorvastatin on apolipoproteins, enzymes and lipid transfer proteins involved in lipoprotein metabolism and inflammatory parameters
I. Karalis (2010)
10.1186/1745-6215-7-35
Comparison of the efficacy and safety of rosuvastatin 10 mg and atorvastatin 20 mg in high-risk patients with hypercholesterolemia – Prospective study to evaluate the Use of Low doses of the Statins Atorvastatin and Rosuvastatin (PULSAR)
M. Clearfield (2006)
10.5551/JAT.19109
Can intensive lipid-lowering therapy improve the carotid intima-media thickness in Japanese subjects under primary prevention for cardiovascular disease?: The JART and JART extension subanalysis.
H. Daida (2014)
10.1016/j.atherosclerosis.2008.09.027
Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: a phase 3 study.
P. Jones (2009)
10.1097/01.TP.0000443225.66960.7e
More Potent Lipid-Lowering Effect by Rosuvastatin Compared With Fluvastatin in Everolimus-Treated Renal Transplant Recipients
Ida Robertsen (2014)
10.1146/ANNUREV.PHARMTOX.45.120403.095748
Pleiotropic effects of statins.
J. Liao (2005)
10.1016/S0002-9343(98)00038-2
Cholesterol lowering in the management of coronary artery disease: the clinical implications of recent trials.
D. Eisenberg (1998)
10.1016/j.amjcard.2008.02.061
Efficacy of rosuvastatin (5 mg and 10 mg) twice a week in patients intolerant to daily statins.
M. Gadarla (2008)
10.1016/S0149-2918(01)80050-3
A comparison of the efficacy and tolerability of titrate-to-goal regimens of simvastatin and fluvastatin: a randomized, double-blind study in adult patients at moderate to high risk for cardiovascular disease.
M. van Dam (2001)
10.1016/j.jacc.2008.04.052
Statin therapy alters the relationship between apolipoprotein B and low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol targets in high-risk patients: the MERCURY II (Measuring Effective Reductions in Cholesterol Using Rosuvastatin) trial.
C. Ballantyne (2008)
10.1016/J.AMJCARD.2003.09.008
Comparisons of effects of statins (atorvastatin, fluvastatin, lovastatin, pravastatin, and simvastatin) on fasting and postprandial lipoproteins in patients with coronary heart disease versus control subjects.
E. Schaefer (2004)
10.1007/s102380300015
Different effect induced by treatment with several statins on monocyte tissue factor expression in hypercholesterolemic subjects
F. Bruni (2003)
10.1016/S0828-282X(10)71075-8
The impact of social determinants on cardiovascular disease.
C. Kreatsoulas (2010)
10.1177/0003319713507333
Comparision of Effects of Rosuvastatin Versus Atorvastatin Treatment on Plasma Levels of Asymmetric Dimethylarginine in Patients With Hyperlipidemia Having Coronary Artery Disease
E. Kurtoğlu (2014)
10.7326/0003-4819-120-7-199404010-00002
Low-Dose Combined Therapy with Fluvastatin and Cholestyramine in Hyperlipidemic Patients
D. Sprecher (1994)
10.1016/S0149-2918(08)80061-6
Cost-effectiveness analysis of rosuvastatin versus atorvastatin, simvastatin, and pravastatin from a Canadian health system perspective.
M. Costa-Scharplatz (2008)
10.1016/J.AMJCARD.2005.08.026
Comparison of efficacy and safety of rosuvastatin versus atorvastatin in African-American patients in a six-week trial.
K. Ferdinand (2006)
10.1097/01.fjc.0000175455.46245.c8
Monocyte Release of Tumor Necrosis Factor-α and Interleukin-1β in Primary Type IIa and IIb Dyslipidemic Patients Treated With Statins or Fibrates
B. Okopień (2005)
Effects of short-term rosuvastatin therapy on heart and kidney function in patients with acute coronary syndrome combining diabetes mellitus and concomitant chronic kidney disease
Heng Wu (2014)
10.2174/157016208786501481
Rosuvastatin, pravastatin, and atorvastatin for the treatment of hypercholesterolaemia in HIV-infected patients receiving protease inhibitors.
L. Calza (2008)
10.1111/j.1365-2362.2009.02249.x
Differential effects of fluvastatin alone or in combination with ezetimibe on lipoprotein subfractions in patients at high risk of coronary events
T. Stojaković (2010)
10.1046/J.1365-2125.1996.03415.X
A comparison of the effects of fluvastatin and bezafibrate on exercise metabolism: a placebo-controlled study in healthy normolipidaemic subjects.
C. Eagles (1996)
10.1016/S0002-9149(05)80027-X
Fluvastatin for dyslipoproteinemia, with or without concomitant chronic renal insufficiency.
C. Lintott (1995)
10.1016/0002-9343(94)90230-5
Fluvastatin administration at bedtime versus with the evening meal: a multicenter comparison of bioavailability, safety, and efficacy.
C. Dujovne (1994)
10.1007/s10557-010-6273-5
Achievement of Lipid Targets with the Combination of Rosuvastatin and Fenofibric Acid in Patients with Type 2 Diabetes Mellitus
R. Rosenson (2010)
10.1001/jama.2012.366
Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis.
S. Boekholdt (2012)
10.1016/j.atherosclerosis.2013.08.013
Comparison of the effect of simvastatin versus simvastatin/ezetimibe versus rosuvastatin on markers of inflammation and oxidative stress in subjects with hypercholesterolemia.
E. Moutzouri (2013)
10.1185/030079907X242809
A randomised study comparing the efficacy and safety of rosuvastatin with atorvastatin for achieving lipid goals in clinical practice in Asian patients at high risk of cardiovascular disease (DISCOVERY-Asia study)
J. Zhu (2007)
Primary PTCA versus thrombolytic therapy for acute MI
Tayo A Addo (2003)
10.1016/S1726-4901(08)70001-7
Efficacy and Safety of Rosuvastatin in Taiwanese Patients
C. Chiang (2008)
10.1016/S0021-9150(00)00567-0
Fluvastatin therapy improves microcirculation in patients with hyperlipidaemia.
E. Haak (2001)
10.1016/S0149-2918(01)80029-1
Comparison of the efficacy and tolerability of fluvastatin extended-release and immediate-release formulations in the treatment of primary hypercholesterolemia: a randomized trial.
A. Olsson (2001)
10.1016/j.curtheres.2004.06.004
Metabolic effects of fluvastatin extended release 80 mg and atorvastatin 20 mg in patients with type 2 diabetes mellitus and low serum high-density lipoprotein cholesterol levels: a 4-month, prospective, open-label, randomized, blinded-end point (probe) trial.
M. Bevilacqua (2004)
Pharmacokinetics and pharmacodynamics of combined use of lopinavir/ritonavir and rosuvastatin in HIV-infected patients.
Manon J van der Lee (2007)
10.5551/JAT.12.41
A comparative crossover study of the effects of fluvastatin and pravastatin (FP-COS) on circulating autoantibodies to oxidized LDL in patients with hypercholesterolemia.
B. Zhang (2005)
10.1111/j.1365-2265.2006.02510.x
The effect of fluvastatin on plasma adiponectin levels in dyslipidaemia
A. Sonmez (2006)
10.1592/PHCO.20.9.819.35197
Pharmacoeconomic assessment of HMG-CoA reductase inhibitor therapy: an analysis based on the CURVES study.
D. Hilleman (2000)
10.1016/S0002-9149(01)01727-1
Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia.
A. Olsson (2001)
Efficacy and safety of rosuvastatin and atorvastatin in aged patients with hypercholesterolemia
Wang Yu-hong (2008)
10.1016/j.amjcard.2010.11.009
Efficacy of fenofibric acid plus statins on multiple lipid parameters and its safety in women with mixed dyslipidemia.
A. Goldberg (2011)
Efficacy of rosuvastatin in the treatment of early diabetic nephropathy
Liu Zhi-hua (2012)
10.5387/FMS.57.19
Fluvastatin increases bone mineral density in postmenopausal women.
Mituhiro Gotoh (2011)
10.1177/107424840400900204
Effects of Antihypertensive and Hypolipidemic Drugs on Plasma and High-Density Lipoprotein-Associated Platelet Activating Factor-Acetylhydrolase Activity
A. Tambaki (2004)
10.1016/J.AMJCARD.2005.01.074
Cost effectiveness of rosuvastatin in treating patients to low-density lipoprotein cholesterol goals compared with atorvastatin, pravastatin, and simvastatin (a US Analysis of the STELLAR Trial).
P. Miller (2005)
10.1016/S0026-0495(99)90239-1
Combined hyperlipidemia is associated with increased exercise-induced muscle protein release which is improved by triglyceride-lowering intervention.
J. Smit (1999)
10.1186/1475-2840-11-153
Angiotensin II type 1 and type 2 receptor expression in circulating monocytes of diabetic and hypercholesterolemic patients over 3-month rosuvastatin treatment
Franca Marino (2012)
10.1016/J.AMJCARD.2004.09.034
Effects of rosuvastatin, atorvastatin, simvastatin, and pravastatin on atherogenic dyslipidemia in patients with characteristics of the metabolic syndrome.
P. Deedwania (2005)
10.1111/j.1463-1326.2004.00450.x
Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial
S. Stender (2005)
10.1111/j.1365-2893.2010.01310.x
Open‐label, ascending dose, prospective cohort study evaluating the antiviral efficacy of Rosuvastatin therapy in serum and lipid fractions in patients with chronic hepatitis C
K. Patel (2011)
10.1016/S0002-9149(05)80017-7
Effects of fluvastatin and pravastatin on lipid profiles and thromboxane production in type IIa hypercholesterolemia.
M. Milani (1995)
10.1016/S0002-9149(05)80016-5
Clinical efficacy of fluvastatin in the long-term treatment of familial hypercholesterolemia.
J. Koizumi (1995)
10.1016/S0011-393X(05)80525-9
Efficacy and safety of fluvastatin in elderly hypercholesterolemic patients : a pilot study
G. Baggio (1994)



This paper is referenced by
10.1007/s12471-017-0959-2
Pathophysiology and treatment of atherosclerosis
S. Bergheanu (2017)
10.1007/s00246-017-1572-2
Potential and Limitations of Cochrane Reviews in Pediatric Cardiology: A Systematic Analysis
Martin Poryo (2017)
10.3389/fmolb.2018.00120
Metabolic Alterations in Cardiopulmonary Vascular Dysfunction
Valérie Françoise Smolders (2019)
10.1080/15284336.2016.1184863
Effect of rosuvastatin on plasma coenzyme Q10 in HIV-infected individuals on antiretroviral therapy
Justin Morrison (2016)
10.1002/14651858.CD012501
Cerivastatin for lowering lipids.
Stephen P. Adams (2017)
10.1007/s12325-016-0412-8
Clinical Implications of Switching Lipid Lowering Treatment from Rosuvastatin to Other Agents in Primary Care
Furio Colivicchi (2016)
10.1002/14651858.CD008226.PUB3
Atorvastatin for lowering lipids
S. Adams (2015)
10.1002/14651858.CD012282.PUB2
فلوواستاتین برای کاهش چربیهای خون
S. Adams (2018)
10.1136/heartjnl-2019-316252
Comparison of lifestyle changes and pharmacological treatment on cardiovascular risk factors
P. Marques-Vidal (2020)
10.1007/s10557-019-06904-x
State of the Art Comprehensive Review of Individual Statins, Their Differences, Pharmacology, and Clinical Implications
Veronica Azemawah (2019)
10.1016/j.amjcard.2017.05.046
Meta-analysis of Placebo-Controlled Randomized Controlled Trials on the Prevalence of Statin Intolerance.
Haris Riaz (2017)
Review on Rosuvastatin
Sri Ch (2016)
10.1002/14651858.CD012735
Pitavastatin for lowering lipids
S. P. Adams (2017)
10.1016/j.jclinepi.2018.05.022
Abbreviated literature searches were viable alternatives to comprehensive searches: a meta-epidemiological study.
B. Nussbaumer-Streit (2018)
Semantic Scholar Logo Some data provided by SemanticScholar